未登录

N

Nathaniel Brown

northwell health

H指数:37

被引数:9,393

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Sleep health and predicted cognitive effectiveness of nurses working 12-hour shifts: an observational study

INTERNATIONAL JOURNAL OF NURSING STUDIES

IF7.1

2020-12-0142

PREAI

Antiviral Activity, Safety, and Pharmacokinetics of Capsid Assembly Modulator NVR 3-778 in Patients with Chronic HBV Infection

GASTROENTEROLOGY

IF25.1

2019-04-01114

OAAI

A research agenda for curing chronic hepatitis B virus infection

治疗慢性乙型肝炎病毒感染的研究议程

IF15.8

2018-01-2470

OAAI

Alter, Harvey; Block, Timothy; Brown, Nathaniel; Brownstein, Alan; Brosgart, Carol; Chang, Kyong-Mi; Chen, Pei-Jer; Chisari, Francis V.; Cohen, Chari; El-Serag, Hashem; Feld, Jordan; Gish, Robert; Glenn, Jeffrey; Greten, Tim; Guo, Haitao; Guo, Ju-Tao; Hoshida, Yujin; Hu, Jianming; Kowdley, Kris V.; Li, Wenhui; Liang, Jake; Locarnini, Stephan; Lok, Anna S.; Mason, William; McMahon, Brian; Mehta, Anand; Perrillo, Robert; Revill, Peter; Rice, Charles M.; Rinaudo, JoAnn; Schinazi, Raymond; Seeger, Christoph; Shetty, Kirty; Tavis, John; Zoulim, Fabien

Effectiveness of ravidasvir plus sofosbuvir in interferon-naive and treated patients with chronic hepatitis C genotype-4

JOURNAL OF HEPATOLOGY

IF33

2018-01-0111

PREAI

NVR 3-778, A FIRST-IN-CLASS HBVCORE INHIBITOR, ALONE AND IN COMBINATION WITH PEG-INTERFERON (PEGIFN), IN TREATMENT-NAIVE HBEAG-POSITIVE PATIENTS: EARLY REDUCTIONS IN HBV DNA AND HBEAG

JOURNAL OF HEPATOLOGY

IF33

2016-01-0145

PREAI

HIGH RATE OF SUSTAINED VIROLOGIC RESPONSE IN PATIENTS WITH HCV GENOTYPE-1A INFECTION: A PHASE 2 TRIAL OF FALDAPREVIR, DELEOBUVIR AND PPI-668, WITH AND WITHOUT RIBAVIRIN

JOURNAL OF HEPATOLOGY

IF33

2014-04-014

PREAI

VAST MAJORITY OF DETECTED NS5A RESISTANT VARIANTS ARE NOT AMPLIFIED IN HCV PATIENTS DURING 3-DAY MONOTHERAPY WITH THE OPTIMIZED NS5A INHIBITOR PPI-668

JOURNAL OF HEPATOLOGY

IF33

2013-04-014

OAAI

Progress towards improving antiviral therapy for hepatitis C with hepatitis C virus polymerase inhibitors. Part I: Nucleoside analogues

EXPERT OPINION ON INVESTIGATIONAL DRUGS

IF4.1

2009-05-09111

PREAI

2-Year GLOBE Trial Results: Telbivudine Is Superior to Lamivudine in Patients With Chronic Hepatitis B

GASTROENTEROLOGY

IF25.1

2009-02-01532

PREAI

Metabolic abnormalities associated with mild cognitive impairment in Parkinson disease

IF8.5

2008-04-15206

OAAI

To define virological response in hepatitis B e antigen-negative patients - Reply

IF15.8

2008-04-011

OAAI

Telbivudine versus lamivudine in Chinese patients with chronic hepatitis B: Results at 1 year of a randomized, double-blind trial

IF15.8

2008-02-01186

PREAI

Abnormal metabolic networks in atypical parkinsonism

MOVEMENT DISORDERS

IF7.6

2008-01-09153

PREAI

Telbivudine versus lamivudine in patients with chronic hepatitis B

NEW ENGLAND JOURNAL OF MEDICINE

IF78.5

2007-12-20681

OA

Pharmacokinetics of telbivudine in subjects with various degrees of renal impairment

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

IF4.5

2007-12-0118

OAAI

Efficacy of telbivudine vs lamivudine at 2 years in patients with HBeAG-positive chronic hepatitis B who are eligible for treatment based on guidelines

JOURNAL OF HEPATOLOGY

IF33

2007-04-016

PREAI

A randomized trial of switching to telbivudine versus continued lamivudine in adults with chronic hepatitis B: Results of the primary analysis at week 24

JOURNAL OF HEPATOLOGY

IF33

2007-04-0113

PREAI

Sustained off-treatment hbeag response in telbivudine and lamivudine treated hbeagpositive patients from the globe study

JOURNAL OF HEPATOLOGY

IF33

2007-04-015

OAAI

76 week follow up of HBeAg-positive chronic hepatitis B patients treated with telbivudine, adefovir or switched from adefovir to telbivudine

JOURNAL OF HEPATOLOGY

IF33

2007-04-015

OAAI

In hepatitis B patients treated with either adefovir or telbivudine, maximal early HBV suppression at 24 weeks predicts optimal one-year efficacy

JOURNAL OF HEPATOLOGY

IF33

2007-04-013

OAAI